]>
IRCT2017061113739N9 IRCT 2017-06-14 Vice-Chancellor for Research, Tehran University of Medical Sciences The therapeutic effect of Glucuronic acid in breast cancer patients Evaluation of the effect of Glucuronic acid on processing of breast cancer disease 2017-07-19 anticipated 36 Complete https://irct.ir/trial/13524 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 1-2 Condition 1: Breast Cancer. Condition 2: Breast Cancer. Condition 3: Breast Cancer. Condition 4: Breast Cancer. Condition 5: Breast Cancer. Condition 6: Breast Cancer. Condition 7: Breast Cancer. Condition 8: Breast Cancer. Intervention 1: The intervention group will receive 1500 mg/day (three 500 mg tablets/day) of Glucuronic acid orally for 12 weeks. The Glucuronic acid produced from the decomposition of Alginate powder (a safe, natural substance used in food and pharmaceutical industries) purchased from Sigma Corporation of U.S.A, in central laboratory of immunology department of School of Public Health and Institute of Health Research of Tehran University of Medical Sciences. Intervention 2: Control group will receive of conventional drugs orally for 12 weeks.
public Dr. Abbas Mirshafiey
Department of pathobiology, School of Public Health, Tehran University of Medical Sciences,16 Azar St ,Enghelab Sq, Tehran, Iran
Tehran Iran (Islamic Republic of) +98 21 8895 4913 mirshafiey@tums.ac.ir Department of pathobiology, School of Public Health, Tehran University of Medical Sciences scientific Dr. Abbas Mirshafiey
Department of pathobiology, School of Public Health, Tehran University of Medical Sciences,16 Azar St ,Enghelab Sq, Tehran, Iran
Tehran Iran (Islamic Republic of) +98 21 8895 4913 mirshafiey@tums.ac.ir Department of pathobiology, School of Public Health, Tehran University of Medical Sciences Iran (Islamic Republic of) Inclusion Criteria: 30-60 years old patients, Diagnosed with breast cancer according to American College of oncology Diagnostic Criteria after the initial visit by a specialist in cancer surgery and parameters CEA, CA15.3, CBC and sonography, Each patient must sign written informed consent. Exclusion Criteria: History of fever and Infectious diseases, Positive pregnancy test or Lactation, Other collagen- vascular and auto immune diseases, Patients have enrolled another clinical trial study within last 4 weeks, Other concomitant diseases (Hepatic, renal, haematological, gastrointestinal, endocrine, cardiovascular, pulmonary, neurological or cerebral disease). 65 years 35 years Female C50.8 C50.2 C50.3 C50.4 C50.5 C50.6 C50.9 C50.0 Malignant neoplasm: overlapping lesion of breast Malignant neoplasm: upper-inner quadrant of breast Malignant neoplasm: lower-inner quadrant of breast Malignant neoplasm: upper-outer quadrant of breast Malignant neoplasm: lower-outer quadrant of breast Malignant neoplasm: axillary tail of breast Malignant neoplasm: breast, unspecified Malignant neoplasm: nipple and areola Treatment - Drugs Treatment - Drugs The intervention group will receive 1500 mg/day (three 500 mg tablets/day) of Glucuronic acid orally for 12 weeks. The Glucuronic acid produced from the decomposition of Alginate powder (a safe, natural substance used in food and pharmaceutical industries) purchased from Sigma Corporation of U.S.A, in central laboratory of immunology department of School of Public Health and Institute of Health Research of Tehran University of Medical Sciences. Control group will receive of conventional drugs orally for 12 weeks. Feel the mass and tenacity in breast. Timepoint: At baseline and after 12 weeks of treatment. Method of measurement: Examination by specialist. Tumor size. Timepoint: At baseline and after 12 weeks of treatment. Method of measurement: Sonography. Vice-Chancellor for Research, Tehran University of Medical Sciences Approved 2017-06-08 Ethics committee of Tehran University of Medical Sciences 6th floorŲŒ central building of Tehran University of Medical SciencesŲŒ On the Corner of Keshavarz Blv Tehran Iran (Islamic Republic of)